All In Biotech

Drug Trial Radar · NCT02657005

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

85

Actual

Start

Aug 2016

Primary completion

May 2022

Study completion Jun 2022

Sponsor

Lead sponsor
Oncternal Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jan 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data in monotherapy and in combination with vincristine to assess the potential of TK216 for further development.

Conditions

  • Sarcoma, Ewing

Interventions

  • TK216Drug

    Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: 36 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Texas Children's Cancer & Hematology Centers, Baylor College

    Houston, Texas

  • UT MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.